Gan & Lee Pharmaceuticals.
24
8
16
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 24 trials
100.0%
+13.5% vs industry average
54%
13 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
Role: lead
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Role: lead
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy
Role: lead
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy
Role: lead
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
Role: lead
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
Role: lead
Bioequivalence Study of GZR18 Injection Before and After CMC Change
Role: lead
A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects
Role: lead
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
Role: lead
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
Role: lead
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
Role: lead
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
Role: lead
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
Role: lead
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin
Role: lead
A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
Role: lead
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
Role: lead
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
Role: lead
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
Role: lead
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
Role: lead
The Study of [14C] GZR18
Role: lead